Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.

ABSTRACT:

Objective

This study assessed the cost-effectiveness of atezolizumab in combination with chemotherapy for patients with advanced or recurrent endometrial cancer (EC) from the U.S. payer's perspective.

Methods

A cost-effectiveness study was conducted using a Markov model based on ENGOT-en7/MaNGO/AtTEnd clinical trials. The population consisted of patients with EC, stratified by mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) subgroups. The model simulated patients receiving either atezolizumab plus chemotherapy or chemotherapy alone. Cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were calculated using a Willingness-to-Pay (WTP) threshold of $150,000/QALY. Sensitivity analyses were performed.

Results

Add

SUBMITTER: Huo G 

PROVIDER: S-EPMC11390248 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature